From Technical Specs to Brand Trust: Global Healthcare Goes Full-Speed Ahead in 2026

At the “2026 Future Healthcare and Pharmaceuticals Top 100 Conference” recently held in Shanghai, leading figures and investors from the global and Chinese healthcare sectors convened. The conference focused not only on technological innovation trends such as AI-driven innovation and end-to-end digitalization, but also on a key challenge facing China’s healthcare globalization strategy: how to genuinely transition from “product export” to “brand export.”

Cai Xiaodan, General Manager of the Marketing Solutions Division at LinkedIn China, stated during the conference that the bottleneck many Chinese healthcare companies encounter in overseas markets is not a lack of product or technological competitiveness, but rather a “disconnect between brand awareness and deep-seated trust.” When overseas buyers have not yet included a company on their “list of trusted suppliers,” decision-making automatically reverts to the simplest criterion: price.

This disconnect occurs against the backdrop of a “structural upgrade.” Industry data shows that China’s medical device export structure has gradually shifted from traditional consumables to equipment and categories with higher technological content: in 2024, medical equipment accounted for 43.6% of exports, while medical consumables made up 38.0%. However, structural upgrading does not equate to an upgrade in trust. Cai Xiaodan believes, “Brand capability is becoming part of a company’s organizational capability. Brand influence is not merely the result of external communication, but an outward manifestation of internal capabilities. In the global market, brands are not ‘created’ through marketing, but ‘forged’ through practice.”

As a global professional platform with 1.3 billion members, LinkedIn brings together 61.3 million healthcare industry practitioners and 10.6 million medical professionals worldwide. Compared to other industries, the healthcare sector has more stringent trust-building mechanisms due to its long decision-making chains, dispersed roles, and high risk sensitivity. Insights from LinkedIn on North American healthcare decision-makers reveal that 54% of them report involving more than four participants in procurement decisions. These participants come not only from procurement and clinical departments but also include “invisible buyers” from finance, legal, business development, and other functions. This means that companies need to influence not just a single individual, but an entire committee-style decision-making chain.

“Many companies mistake visibility for trust, but in the overseas healthcare market, visibility is only the beginning.” Cai Xiaodan pointed out that overseas buyers rarely search for a new brand from scratch; instead, they more commonly complete pre-screening through long-term observation: whether the company consistently produces professional content, whether its management team communicates with stability, and whether it has third-party endorsements (international certifications, benchmark cases, and authentic testimonials from experts and customers). When these signals are absent, procurement decisions revert to the lowest-risk options, with price often becoming the only comparable factor.

To transform trust into a replicable growth pathway, Cai Xiaodan offers the following key strategy: enter the “gateway of trust” and turn content into assets that are “verifiable, accumulable, and convertible.” She emphasizes that the most efficient route for medical enterprises expanding overseas is not to “cast a wider net,” but to “dig deeper”: first, establish a publicly shareable benchmark case in a key market; then build academic mutual trust through experts, KOLs, and customer testimonials; and finally, leverage long-form content such as white papers and webinars to facilitate evaluation and conversion.

LinkedIn platform research data shows: “87% of B2B buyers are more inclined to trust reliable industry experts or opinion leaders. Meanwhile, video is becoming an efficient medium, with 63% of purchasing decision-makers hoping to use video content to assist in their buying decisions.”

On the practical front, a growing number of enterprises are replacing “single-point advertising” with a “content matrix.” For instance, leading overseas CDMOs are building top-of-funnel awareness on LinkedIn by highlighting their technology platforms, regulatory compliance capabilities, and manufacturing infrastructure, while continuously nurturing mid- and bottom-funnel prospects through carousel ads, document ads, and webinars.

Furthermore, a Chinese biotechnology enterprise collaborated with authoritative industry scientists to create in-depth marketing content and establish industry leadership, resulting in an increase in click-through rate (CTR) from ≤0.8% to ≥1.6% and driving a 22% rise in brand awareness.

For Chinese leaders in the healthcare and wellness sector who are accelerating their global expansion, product strength is the entry ticket, but trustworthiness is the true litmus test. Marketing in the AI era can be faster and more precise, yet it cannot bridge cultural divides or foster emotional resonance. The key to brand marketing for future healthcare enterprises lies in integrating technology with humanity to build brands with warmth. After all, in the healthcare industry, buyers are never purchasing mere product specifications; they are investing in “safety, reliability, and trust.”